RxDoctor Payments Data

Mark Thompson, MD

Cardiovascular Disease · Chicago, ILNPI 1750588661

Payments from drug & device makers

$11,348in general payments, 2019–2025

Across 123 payments — averaging $92.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
  • Novartis$569
  • AstraZeneca$505
  • Johnson & Johnson$246
  • Boston Scientific$168
  • Lexicon Pharmaceuticals, Inc.$162
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$6,75059%
  • Food & beverage$4,59841%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,348 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$78,345
Medicare patients
329
Services billed
768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan235$214,457
EliquisApixaban91$91,918
Repatha SureclickEvolocumab59$33,376
XareltoRivaroxaban36$32,444
FarxigaDapagliflozin Propanediol35$30,822
BrilintaTicagrelor40$30,167
JardianceEmpagliflozin22$30,011
Metoprolol Succinate261$3,164
Carvedilol240$1,793
Atorvastatin Calcium202$1,739
Valsartan59$1,481
Rosuvastatin Calcium73$1,469
Amlodipine Besylate174$1,449
Ranolazine ErRanolazine11$1,211
Nifedipine ErNifedipine35$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$569$214,457235 claims
PfizerEliquis$31$91,91891 claims
AstraZenecaFarxiga, Brilinta$505$60,98975 claims
Johnson & JohnsonXarelto$246$32,44436 claims
Boehringer IngelheimJardiance$91$30,01122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →